In Clinical Trials: A Potential Self-Administered Treatment for Diabetic Macular Edema
Aerpio Therapeutics, Inc. is a new Cincinnati, Ohio-based biopharmaceutical company focused on developing new therapies for vascular [i.e., blood vessel] diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD). This week, Aerpio announced positive clinical trial results for AKB-9778, which shows potential for self-administered subcutaneous [i.e., beneath-the-skin injection] treatment of DME, offering an … Continued